Aurora Cannabis (ACB) Competitors $4.24 +0.06 (+1.44%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends ACB vs. AVBP, NUVB, ETNB, TYRA, RAPP, RLAY, EOLS, PLRX, CRON, and PRTAShould you be buying Aurora Cannabis stock or one of its competitors? The main competitors of Aurora Cannabis include ArriVent BioPharma (AVBP), Nuvation Bio (NUVB), 89bio (ETNB), Tyra Biosciences (TYRA), Rapport Therapeutics (RAPP), Relay Therapeutics (RLAY), Evolus (EOLS), Pliant Therapeutics (PLRX), Cronos Group (CRON), and Prothena (PRTA). These companies are all part of the "pharmaceutical products" industry. Aurora Cannabis vs. ArriVent BioPharma Nuvation Bio 89bio Tyra Biosciences Rapport Therapeutics Relay Therapeutics Evolus Pliant Therapeutics Cronos Group Prothena Aurora Cannabis (NASDAQ:ACB) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, community ranking, valuation, dividends and risk. Does the MarketBeat Community favor ACB or AVBP? Aurora Cannabis received 365 more outperform votes than ArriVent BioPharma when rated by MarketBeat users. However, 100.00% of users gave ArriVent BioPharma an outperform vote while only 59.44% of users gave Aurora Cannabis an outperform vote. CompanyUnderperformOutperformAurora CannabisOutperform Votes38159.44% Underperform Votes26040.56% ArriVent BioPharmaOutperform Votes16100.00% Underperform VotesNo Votes Does the media favor ACB or AVBP? In the previous week, ArriVent BioPharma had 5 more articles in the media than Aurora Cannabis. MarketBeat recorded 9 mentions for ArriVent BioPharma and 4 mentions for Aurora Cannabis. Aurora Cannabis' average media sentiment score of 0.75 beat ArriVent BioPharma's score of 0.54 indicating that Aurora Cannabis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurora Cannabis 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ArriVent BioPharma 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Do institutionals & insiders believe in ACB or AVBP? 47.6% of Aurora Cannabis shares are held by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are held by institutional investors. 0.0% of Aurora Cannabis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts recommend ACB or AVBP? ArriVent BioPharma has a consensus price target of $36.80, indicating a potential upside of 34.26%. Given ArriVent BioPharma's higher possible upside, analysts clearly believe ArriVent BioPharma is more favorable than Aurora Cannabis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aurora Cannabis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00ArriVent BioPharma 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable earnings and valuation, ACB or AVBP? Aurora Cannabis has higher revenue and earnings than ArriVent BioPharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAurora Cannabis$200.35M1.16-$48.62M-$0.76-5.58ArriVent BioPharmaN/AN/A-$69.33MN/AN/A Is ACB or AVBP more profitable? ArriVent BioPharma has a net margin of 0.00% compared to Aurora Cannabis' net margin of -17.47%. Aurora Cannabis' return on equity of -2.19% beat ArriVent BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets Aurora Cannabis-17.47% -2.19% -1.56% ArriVent BioPharma N/A -43.89%-29.67% SummaryAurora Cannabis beats ArriVent BioPharma on 8 of the 13 factors compared between the two stocks. Ad DTIWhen it comes to NVDA… “acceleration cycles” are the keyExpert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.Use this link to see Nvidia Unchained right away! Get Aurora Cannabis News Delivered to You Automatically Sign up to receive the latest news and ratings for ACB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACB vs. The Competition Export to ExcelMetricAurora CannabisMedicinals & botanicals IndustryMedical SectorNASDAQ ExchangeMarket Cap$232.52M$1.23B$5.01B$8.81BDividend YieldN/AN/A5.21%4.07%P/E Ratio-5.5846.01126.5217.52Price / Sales1.169.141,203.9085.12Price / Cash18.7911.9233.3732.51Price / Book0.522.164.684.68Net Income-$48.62M-$51.67M$118.36M$225.62M7 Day Performance-6.61%-5.85%-2.46%-2.04%1 Month Performance-24.15%-3.98%-4.06%0.03%1 Year Performance-11.02%5.22%29.55%24.47% Aurora Cannabis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACBAurora Cannabis0.6391 of 5 stars$4.24+1.4%N/A-11.0%$232.52M$200.35M-5.581,073AVBPArriVent BioPharma1.0036 of 5 stars$27.410.0%$36.80+34.3%N/A$923.64MN/A0.0040NUVBNuvation Bio2.7307 of 5 stars$2.59flat$6.60+155.3%+91.5%$871.71MN/A0.0060ETNB89bio1.4925 of 5 stars$7.98-0.1%$30.33+280.1%+3.1%$846.89MN/A-2.7440TYRATyra Biosciences3.0819 of 5 stars$15.87-2.1%$31.00+95.3%+40.8%$820.27MN/A0.0020RAPPRapport Therapeutics1.8487 of 5 stars$22.19-0.4%$35.00+57.7%N/A$814.92MN/A0.00N/ANews CoverageRLAYRelay Therapeutics3.2705 of 5 stars$4.66-2.9%$21.22+355.4%-44.5%$803.44M$25.55M0.00304Gap DownHigh Trading VolumeEOLSEvolus4.0221 of 5 stars$12.63+1.9%$23.00+82.1%+28.4%$799.73M$202.09M-13.88170Positive NewsPLRXPliant Therapeutics3.4806 of 5 stars$12.73-0.5%$40.57+218.7%-11.4%$778.32M$1.58M0.0090CRONCronos Group1.7734 of 5 stars$2.01-1.0%$3.00+49.3%-3.8%$776.06M$87.24M0.00356PRTAProthena1.6434 of 5 stars$14.40+2.5%$61.86+329.6%-57.8%$756.01M$91.37M0.00173Analyst DowngradeAnalyst Revision Related Companies and Tools Related Companies ArriVent BioPharma Competitors Nuvation Bio Competitors 89bio Competitors Tyra Biosciences Competitors Rapport Therapeutics Competitors Relay Therapeutics Competitors Evolus Competitors Pliant Therapeutics Competitors Cronos Group Competitors Prothena Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ACB) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aurora Cannabis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aurora Cannabis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACB Stock Alerts